143 related articles for article (PubMed ID: 25449686)
21. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
22. The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia.
Georgoulia PS; Todde G; Bjelic S; Friedman R
Biochim Biophys Acta Gen Subj; 2019 Apr; 1863(4):732-741. PubMed ID: 30684523
[TBL] [Abstract][Full Text] [Related]
23. Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea.
Cho YU; Kim SO; Chi HS; Park SJ; Jang S; Park CJ; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ; Hong SP
Int J Lab Hematol; 2013 Dec; 35(6):589-600. PubMed ID: 23575252
[TBL] [Abstract][Full Text] [Related]
24. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
25. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
26. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.
Masuzawa A; Kiyotani C; Osumi T; Shioda Y; Iijima K; Tomita O; Nakabayashi K; Oboki K; Yasuda K; Sakamoto H; Ichikawa H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Mori T
Eur J Haematol; 2014 Mar; 92(3):263-7. PubMed ID: 24215620
[TBL] [Abstract][Full Text] [Related]
27. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Gniot M; Wasilewska EM; Lewandowski K
Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
[No Abstract] [Full Text] [Related]
28. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia.
Ernst T; Score J; Deininger M; Hidalgo-Curtis C; Lackie P; Ershler WB; Goldman JM; Cross NC; Grand F
Br J Haematol; 2011 Apr; 153(1):43-6. PubMed ID: 21391972
[TBL] [Abstract][Full Text] [Related]
29. RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.
Inokuchi K; Wakita S; Hirakawa T; Tamai H; Yokose N; Yamaguchi H; Dan K
Int J Hematol; 2011 Sep; 94(3):255-260. PubMed ID: 21863287
[TBL] [Abstract][Full Text] [Related]
30. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
Boer JM; den Boer ML
Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
[TBL] [Abstract][Full Text] [Related]
31. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
32. Asciminib as a new option in the treatment of chronic myeloid leukemia.
İbiş B; Tiribelli M; Eşkazan AE
Future Oncol; 2021 Dec; 17(36):5003-5005. PubMed ID: 34791894
[No Abstract] [Full Text] [Related]
33. CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels.
Pan Y; Lou J; Wang H; An N; Chen H; Zhang Q; Du X
Blood Cells Mol Dis; 2018 Nov; 73():38-44. PubMed ID: 30224298
[TBL] [Abstract][Full Text] [Related]
34. Computational and Biological Investigations on Abl1 Tyrosine Kinase: A Review.
Sobhia ME; Kumar GS; Mallick A; Singh H; Kumar K; Chaurasiya M; Singh M; Gera N; Deverakonda S; Baghel V
Curr Drug Targets; 2021; 22(1):38-51. PubMed ID: 33050861
[TBL] [Abstract][Full Text] [Related]
35. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
[TBL] [Abstract][Full Text] [Related]
36. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
37. Acute lymphoblastic leukemia associated with RCSD1-ABL1 novel fusion gene has a distinct gene expression profile from BCR-ABL1 fusion.
De Braekeleer E; Douet-Guilbert N; Guardiola P; Rowe D; Mustjoki S; Zamecnikova A; Al Bahar S; Jaramillo G; Berthou C; Bown N; Porkka K; Ochoa C; De Braekeleer M
Leukemia; 2013 Jun; 27(6):1422-4. PubMed ID: 23168614
[No Abstract] [Full Text] [Related]
38. Chromosomal aberrations and fusion genes in myeloid malignancies.
Gianfelici V; Lahortiga I; Cools J
Expert Rev Hematol; 2012 Aug; 5(4):381-93. PubMed ID: 22992233
[TBL] [Abstract][Full Text] [Related]
39. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
Short NJ; Kantarjian H; Kanagal-Shamanna R; Sasaki K; Ravandi F; Cortes J; Konopleva M; Issa GC; Kornblau SM; Garcia-Manero G; Garris R; Higgins J; Pratt G; Williams LN; Valentine CC; Rivera VM; Pritchard J; Salk JJ; Radich J; Jabbour E
Blood Cancer J; 2020 May; 10(5):61. PubMed ID: 32457305
[TBL] [Abstract][Full Text] [Related]
40. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
